WO2019094819A3 - Intravenous delivery systems for chemotherapy drugs - Google Patents

Intravenous delivery systems for chemotherapy drugs Download PDF

Info

Publication number
WO2019094819A3
WO2019094819A3 PCT/US2018/060160 US2018060160W WO2019094819A3 WO 2019094819 A3 WO2019094819 A3 WO 2019094819A3 US 2018060160 W US2018060160 W US 2018060160W WO 2019094819 A3 WO2019094819 A3 WO 2019094819A3
Authority
WO
WIPO (PCT)
Prior art keywords
intravenous
intravenous delivery
delivery systems
diluent
mass
Prior art date
Application number
PCT/US2018/060160
Other languages
French (fr)
Other versions
WO2019094819A2 (en
Inventor
Salah U. Ahmed
Yanming Zu
Tahseen A. Chowdhury
Mukta RAHMAN
Hetalben Prajapati
Gaus M. KHAN
Original Assignee
Abon Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abon Pharmaceuticals, Llc filed Critical Abon Pharmaceuticals, Llc
Publication of WO2019094819A2 publication Critical patent/WO2019094819A2/en
Publication of WO2019094819A3 publication Critical patent/WO2019094819A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is related to an intravenous delivery system for a chemotherapy drug, e.g., an irritating chemotherapy drug, comprising, (a) a lyophilized mass comprising the chemotherapy drug; and (b) a diluent capable of dispersing the mass, wherein the diluent is compatible with intravenous infusion fluids and is suitable for intravenous administration; wherein when the diluent disperses the mass and is placed in intravenous infusion fluids, the intravenous delivery system provides for reduced injection site reaction for a subject administered the intravenous infusion fluids.
PCT/US2018/060160 2017-11-09 2018-11-09 Intravenous delivery systems for chemotherapy drugs WO2019094819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584031P 2017-11-09 2017-11-09
US62/584,031 2017-11-09

Publications (2)

Publication Number Publication Date
WO2019094819A2 WO2019094819A2 (en) 2019-05-16
WO2019094819A3 true WO2019094819A3 (en) 2020-03-26

Family

ID=66438648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/060160 WO2019094819A2 (en) 2017-11-09 2018-11-09 Intravenous delivery systems for chemotherapy drugs

Country Status (1)

Country Link
WO (1) WO2019094819A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074600A1 (en) * 2022-10-05 2024-04-11 Institut Gustave Roussy An oral liquid composition of vinorelbine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952566A (en) * 1987-08-05 1990-08-28 Sumitomo Pharmaceuticals Co., Ltd. Stabilized anthracycline preparation containing L-cysteine
WO2001019338A1 (en) * 1999-09-16 2001-03-22 Pharmacia Italia S.P.A. Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
US20030073665A1 (en) * 2001-03-20 2003-04-17 Thompson Diane O. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN101032475A (en) * 2007-04-03 2007-09-12 北京世纪博康医药科技有限公司 Medical combination of Carmustine, the preparing method and use thereof
CN101176707A (en) * 2007-12-06 2008-05-14 济南帅华医药科技有限公司 Carmustine sustained-release implantation agent for curing entity tumour
WO2009073224A1 (en) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Methods of treating certain diseases using pyrimidine derivatives
US20110206732A1 (en) * 2007-08-21 2011-08-25 Giampiero Pescarmona Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin
US20160067304A1 (en) * 2013-12-27 2016-03-10 Celgene Corporation Romidepsin formulations and uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952566A (en) * 1987-08-05 1990-08-28 Sumitomo Pharmaceuticals Co., Ltd. Stabilized anthracycline preparation containing L-cysteine
WO2001019338A1 (en) * 1999-09-16 2001-03-22 Pharmacia Italia S.P.A. Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
US20030073665A1 (en) * 2001-03-20 2003-04-17 Thompson Diane O. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CN101032475A (en) * 2007-04-03 2007-09-12 北京世纪博康医药科技有限公司 Medical combination of Carmustine, the preparing method and use thereof
US20110206732A1 (en) * 2007-08-21 2011-08-25 Giampiero Pescarmona Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin
CN101176707A (en) * 2007-12-06 2008-05-14 济南帅华医药科技有限公司 Carmustine sustained-release implantation agent for curing entity tumour
WO2009073224A1 (en) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Methods of treating certain diseases using pyrimidine derivatives
US20160067304A1 (en) * 2013-12-27 2016-03-10 Celgene Corporation Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
WO2019094819A2 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
WO2019032482A3 (en) Hydraulic-pneumatic pressurized chamber drug delivery system
WO2016172396A3 (en) Multi-chamber sequential delivery syringe
WO2014169081A3 (en) Methods and devices for point of use mixing of pharmaceutical formulations
MX2023011540A (en) Drive assembly and spacer for drug delivery system.
MX2018012967A (en) Medical delivery system.
WO2012015781A3 (en) Blunt needle safety drug delivery system
WO2015038818A3 (en) Liquid protein formulations containing viscosity-lowering agents
BR112012019549A2 (en) reservoir for use in a medicament module, medicament module comprising that reservoir and drug delivery device.
MX2015006503A (en) Infusion adapter for drug transfer assembly.
MX2016009379A (en) Ported catheter adapter with integrated septum actuator retention.
AR076721A1 (en) MEDICINAL MODULE WITH INTEGRAL FLOW DISTRIBUTION SYSTEM
AU2015300944B2 (en) Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
CR8910A (en) DOSAGE CONTROL FOR DRUG ADMINISTRATION SYSTEMS
WO2014204894A3 (en) Vial transfer and injection apparatus and method
WO2017189258A3 (en) Microneedle array assembly, drug delivery device and method for administering liquid across a broad area at low pressure
NZ718062A (en) Assembly for sequentially delivering substances, and associated methods
WO2008060964A3 (en) Unit dosage package and methods for administering weight loss medications
BR112014029507A2 (en) three component mixing equipment and three component mixing adhesive kit
CA2895719A1 (en) Medical infusion system allowing automatic priming
JP2018525060A5 (en)
WO2011159930A3 (en) Damping systems for stabilizing medications in drug delivery devices
EP3777924A4 (en) Pre-filled syringe, liquid medicine administration system, and syringe pump
WO2013117659A3 (en) Drug delivery apparatus
MX2018001499A (en) Liquid polymer delivery system for extended administration of drugs.
WO2019092469A8 (en) Handheld drug delivery device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18876113

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18876113

Country of ref document: EP

Kind code of ref document: A2